FindTrial
Sign In

Effects of the treatment of continuous positive airway pressure to the aldosterone level in type 2 diabetic patients with OSAHS

Aldosterone levels in patients with moderate to severe OSAS before and after CPAP treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ION-16009837
Enrollment
Unknown
Registered
2016-11-13
Start date
2013-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetic patients with OSAHS

Interventions

The experimental group (diabetes mellitus complicated with severe OSAHS) :CPAP treatment for 7 consecutive days
The control group (DM without OSAHS):no intervention

Sponsors

Beijing Hospital of Ministry of Public Health
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age: 20-80; BMI<35kg/m2; without CPAP or surgical treatment history (uvula Hubei pharyngoplasty); with WHO criteria for the diagnosis of type 2 diabetes mellitus; Department of ENT examination without nasal polyps, tonsil hypertrophy of uvula; Blood pressure control in patients with hypertension stable, and at least 2 weeks before the test to discontinuation the original antihypertensive drugs : diuretics, beta blockers, ACEI and ARB, CCB class of antihypertensive drugs, replaced by Vera Pammy 240mgQd sustained-release tablets; The experimental group (diabetes mellitus complicated with severe OSAHS) Resmed polysomnography was AHI = 15; The control group (DM without OSAHS)Resmed AHI<5 was measured by OSAHS (3 months). The results were compared with the control group.

Exclusion criteria

Exclusion criteria: Severe heart disease (acute myocardial infarction, chronic heart failure, valvular heart disease, and heart failure within 6 months) .Severe renal disease (acute and chronic renal insufficiency, nephrotic syndrome, nephritis, etc.) Serious lung disease (pulmonary bullae, pneumothorax, mediastinal emphysema, pulmonary fibrosis, tumor COPD, etc.) Mental illness, brain injury or cerebrovascular disease .Diabetic ketoacidosis, diabetes, high blood sugar, hypothyroidism, pituitary and adrenal insufficiency.

Design outcomes

Primary

MeasureTime frame
Plasma aldosterone on erect and supine positions;Plasma renin on erect and supine positions;24 h urinary aldosterone;—

Secondary

MeasureTime frame
blood glucose;—

Countries

China

Contacts

Public ContactLixin Guo

Beijing Hospital of Ministry of Public Health

glx1218@163.com+86 13901317569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026